SeraCare Precision Medicine Business Unit Launches First Product

July 20, 2015

The new precision medicine business unit of SeraCare Life Sciences, Milford, Mass, has launched its first product, the Seraseq solid tumor mutation mix I. The biosynthetic reference material is designed to evaluate the performance of next-generation-sequencing (NGS)-based tumor profiling assays. Containing a mixture of mutations in key oncogenes and tumor suppressor genes, the product is intended as a quality material for translational and disease research testing. In addition, it permits laboratories to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics parameters